Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study of Bucillamine in the potential treatment of COVID-19 in APAC countries

Trial Profile

A clinical study of Bucillamine in the potential treatment of COVID-19 in APAC countries

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 08 Apr 2020

At a glance

  • Drugs Bucillamine (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Apr 2020 According to a Revive Therapeutics media release, company has retained Novotech to serve as the Company CRO to pursue future human clinical studies for Bucillamine in the treatment of infectious diseases, including the coronavirus disease (COVID-19) in Asia-Pacific Countries.
    • 01 Apr 2020 New trial record
    • 30 Mar 2020 According to an Revive Therapeutics media release, the company seeks to expand the clinical investigation of Bucillamine for COVID-19 in APAC regions, with a particular interest in Japan and South Korea.

Trial Overview

Purpose

This study will evaluate Bucillamine in the potential treatment of COVID-19.

Diseases Treated

Indication Qualifiers Patient Segments
COVID 2019 infections treatment -

Subjects

  • Subject Type patients
  • Sex male & female

Trial Details

Organisations

  • Affiliations Revive Therapeutics

Trial Dates

Other Details

  • Design multicentre; prospective
  • Phase of Trial Phase II
  • Location Asia-Pacific; Japan; South Korea
  • Focus Therapeutic Use

Interventions

Drugs Route Formulation
BucillaminePrimary Drug
-
-

Bucillamine

Trial History

Event Date Event Type Comment
08 Apr 2020 Other trial event According to a Revive Therapeutics media release, company has retained Novotech to serve as the Company CRO to pursue future human clinical studies for Bucillamine in the treatment of infectious diseases, including the coronavirus disease (COVID-19) in Asia-Pacific Countries. Updated 13 Apr 2020
01 Apr 2020 New trial record New trial record Updated 01 Apr 2020
30 Mar 2020 Other trial event According to an Revive Therapeutics media release, the company seeks to expand the clinical investigation of Bucillamine for COVID-19 in APAC regions, with a particular interest in Japan and South Korea. Updated 01 Apr 2020

References

  1. Revive Therapeutics. Revive Therapeutics Provides Corporate Update on its COVID-19 and Infectious Diseases Programs. Media-Rel 2020;.

    Media Release
  2. Revive Therapeutics, Novotech. Revive Therapeutics Engages Novotech as Asia-Pacific CRO for Bucillamine in the Treatment of Infectious Diseases. Media-Rel 2020;.

    Media Release
Back to top